Last 12 months
Inside the activity.
3 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 3 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 02, 2019 Filed Jul 3, 2019 20:06 UTC |
DAMELIO FRANK AExecutive Vice President
|
SaleCommon Stock | 18,036 | $44.11 | $795,567.96 |
DisclosureSEC source: 0001225208-19-010036 · doc4.xml · nonDerivative · entry 19 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 356,559 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 4, 2019. Read SEC document |
| July 02, 2019 Filed Jul 3, 2019 20:06 UTC |
DAMELIO FRANK AExecutive Vice President
|
SaleCommon Stock | 13,848 | $44.05 | $610,004.40 |
DisclosureSEC source: 0001225208-19-010036 · doc4.xml · nonDerivative · entry 18 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 374,595 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 4, 2019. Read SEC document |
| July 02, 2019 Filed Jul 3, 2019 20:06 UTC |
DAMELIO FRANK AExecutive Vice President
|
SaleCommon Stock | 13,138 | $44.09 | $579,254.42 |
DisclosureSEC source: 0001225208-19-010036 · doc4.xml · nonDerivative · entry 17 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 388,443 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 4, 2019. Read SEC document |
| July 02, 2019 Filed Jul 3, 2019 20:06 UTC |
DAMELIO FRANK AExecutive Vice President
|
SaleCommon Stock | 10,957 | $44.00 | $482,108.00 |
DisclosureSEC source: 0001225208-19-010036 · doc4.xml · nonDerivative · entry 16 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 401,581 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 4, 2019. Read SEC document |
| July 02, 2019 Filed Jul 3, 2019 20:06 UTC |
DAMELIO FRANK AExecutive Vice President
|
SaleCommon Stock | 9,362 | $44.06 | $412,489.72 |
DisclosureSEC source: 0001225208-19-010036 · doc4.xml · nonDerivative · entry 15 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 412,538 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 4, 2019. Read SEC document |
| July 02, 2019 Filed Jul 3, 2019 20:06 UTC |
DAMELIO FRANK AExecutive Vice President
|
SaleCommon Stock | 8,159 | $44.15 | $360,219.85 |
DisclosureSEC source: 0001225208-19-010036 · doc4.xml · nonDerivative · entry 14 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 421,900 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 4, 2019. Read SEC document |
| July 02, 2019 Filed Jul 3, 2019 20:06 UTC |
DAMELIO FRANK AExecutive Vice President
|
SaleCommon Stock | 7,787 | $44.07 | $343,173.09 |
DisclosureSEC source: 0001225208-19-010036 · doc4.xml · nonDerivative · entry 13 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 430,059 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 4, 2019. Read SEC document |
| July 02, 2019 Filed Jul 3, 2019 20:06 UTC |
DAMELIO FRANK AExecutive Vice President
|
SaleCommon Stock | 7,588 | $44.01 | $333,947.88 |
DisclosureSEC source: 0001225208-19-010036 · doc4.xml · nonDerivative · entry 12 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 437,846 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 4, 2019. Read SEC document |
| July 02, 2019 Filed Jul 3, 2019 20:06 UTC |
DAMELIO FRANK AExecutive Vice President
|
SaleCommon Stock | 7,450 | $44.17 | $329,066.50 |
DisclosureSEC source: 0001225208-19-010036 · doc4.xml · nonDerivative · entry 11 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 445,434 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 4, 2019. Read SEC document |
| July 02, 2019 Filed Jul 3, 2019 20:06 UTC |
DAMELIO FRANK AExecutive Vice President
|
SaleCommon Stock | 7,272 | $44.04 | $320,258.88 |
DisclosureSEC source: 0001225208-19-010036 · doc4.xml · nonDerivative · entry 10 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 452,884 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 4, 2019. Read SEC document |
| July 02, 2019 Filed Jul 3, 2019 20:06 UTC |
DAMELIO FRANK AExecutive Vice President
|
SaleCommon Stock | 6,180 | $44.16 | $272,908.80 |
DisclosureSEC source: 0001225208-19-010036 · doc4.xml · nonDerivative · entry 9 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 460,156 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 4, 2019. Read SEC document |
| July 02, 2019 Filed Jul 3, 2019 20:06 UTC |
DAMELIO FRANK AExecutive Vice President
|
SaleCommon Stock | 4,864 | $44.08 | $214,405.12 |
DisclosureSEC source: 0001225208-19-010036 · doc4.xml · nonDerivative · entry 8 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 466,336 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 4, 2019. Read SEC document |
| July 02, 2019 Filed Jul 3, 2019 20:06 UTC |
DAMELIO FRANK AExecutive Vice President
|
SaleCommon Stock | 4,824 | $44.18 | $213,124.32 |
DisclosureSEC source: 0001225208-19-010036 · doc4.xml · nonDerivative · entry 7 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 471,200 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 4, 2019. Read SEC document |
| July 02, 2019 Filed Jul 3, 2019 20:06 UTC |
DAMELIO FRANK AExecutive Vice President
|
SaleCommon Stock | 3,425 | $44.14 | $151,179.50 |
DisclosureSEC source: 0001225208-19-010036 · doc4.xml · nonDerivative · entry 6 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 476,024 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 4, 2019. Read SEC document |
| July 02, 2019 Filed Jul 3, 2019 20:06 UTC |
DAMELIO FRANK AExecutive Vice President
|
SaleCommon Stock | 3,403 | $44.02 | $149,800.06 |
DisclosureSEC source: 0001225208-19-010036 · doc4.xml · nonDerivative · entry 5 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 479,449 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 4, 2019. Read SEC document |
| July 02, 2019 Filed Jul 3, 2019 20:06 UTC |
DAMELIO FRANK AExecutive Vice President
|
SaleCommon Stock | 3,008 | $44.12 | $132,712.96 |
DisclosureSEC source: 0001225208-19-010036 · doc4.xml · nonDerivative · entry 4 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 482,852 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 4, 2019. Read SEC document |
| July 02, 2019 Filed Jul 3, 2019 20:06 UTC |
DAMELIO FRANK AExecutive Vice President
|
SaleCommon Stock | 2,787 | $44.03 | $122,711.61 |
DisclosureSEC source: 0001225208-19-010036 · doc4.xml · nonDerivative · entry 3 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 485,860 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 4, 2019. Read SEC document |
| July 02, 2019 Filed Jul 3, 2019 20:06 UTC |
DAMELIO FRANK AExecutive Vice President
|
SaleCommon Stock | 1,000 | $44.19 | $44,190.00 |
DisclosureSEC source: 0001225208-19-010036 · doc4.xml · nonDerivative · entry 2 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 488,647 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 4, 2019. Read SEC document |
| July 02, 2019 Filed Jul 3, 2019 20:06 UTC |
DAMELIO FRANK AExecutive Vice President
|
SaleCommon Stock | 929 | $44.13 | $40,996.77 |
DisclosureSEC source: 0001225208-19-010036 · doc4.xml · nonDerivative · entry 1 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 489,647 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 4, 2019. Read SEC document |
| June 28, 2019 Filed Jul 1, 2019 23:44 UTC |
BOURLA ALBERTDirector · Chief Executive Officer
|
GrantPhantom Stock Units SSP · Derivative | 23 | $43.32 | $996.36 |
DisclosureSEC source: 0001225208-19-009709 · doc4.xml · derivative · entry 1 BOURLA ALBERT · CIK 0001595703 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,099 Underlying: Common Stock · 23 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| June 28, 2019 Filed Jul 1, 2019 23:44 UTC |
JOHNSON RADY AExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 4 | $43.32 | $173.28 |
DisclosureSEC source: 0001225208-19-009710 · doc4.xml · derivative · entry 1 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,900 Underlying: Common Stock · 4 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| June 28, 2019 Filed Jul 1, 2019 23:44 UTC |
ROGERS DAWNExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 43 | $43.32 | $1,862.76 |
DisclosureSEC source: 0001225208-19-009711 · doc4.xml · derivative · entry 1 ROGERS DAWN · CIK 0001742308 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,733 Underlying: Common Stock · 43 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| June 28, 2019 Filed Jul 1, 2019 23:44 UTC |
YOUNG JOHN DGroup President
|
GrantPhantom Stock Units SSP · Derivative | 10 | $43.32 | $433.20 |
DisclosureSEC source: 0001225208-19-009712 · doc4.xml · derivative · entry 1 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,736 Underlying: Common Stock · 10 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| June 28, 2019 Filed Jul 2, 2019 00:55 UTC |
Echevarria JosephDirector
|
GrantPhantom Stock Units · Derivative | 995.5 | $43.32 | $43,125.06 |
DisclosureSEC source: 0001225208-19-009713 · doc4.xml · derivative · entry 1 Echevarria Joseph · CIK 0001633137 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,778.043 Underlying: Common Stock · 995.5 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units represent deferred director's compensation (including dividend equivalents thereon) that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. F2 · derivative.expiration_date: These units represent deferred director's compensation (including dividend equivalents thereon) that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. Read SEC document |
| June 28, 2019 Filed Jul 2, 2019 00:55 UTC |
KILTS JAMES MDirector
|
GrantPhantom Stock Units · Derivative | 793.51 | $43.32 | $34,374.85 |
DisclosureSEC source: 0001225208-19-009714 · doc4.xml · derivative · entry 1 KILTS JAMES M · CIK 0001025094 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,247.2 Underlying: Common Stock · 793.51 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units represent deferred director's compensation (including dividend equivalents thereon) that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. F2 · derivative.expiration_date: These units represent deferred director's compensation (including dividend equivalents thereon) that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. Read SEC document |
| June 28, 2019 Filed Jul 2, 2019 00:55 UTC |
NARAYEN SHANTANUDirector
|
GrantPhantom Stock Units · Derivative | 1,082.06 | $43.32 | $46,874.84 |
DisclosureSEC source: 0001225208-19-009715 · doc4.xml · derivative · entry 1 NARAYEN SHANTANU · CIK 0001224154 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,117.76 Underlying: Common Stock · 1,082.06 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units represent deferred director's compensation (including dividend equivalents thereon) that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. F2 · derivative.expiration_date: These units represent deferred director's compensation (including dividend equivalents thereon) that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. Read SEC document |
| June 28, 2019 Filed Jul 2, 2019 00:55 UTC |
SMITH JAMES CDirector
|
GrantPhantom Stock Units · Derivative | 966.644 | $43.32 | $41,875.02 |
DisclosureSEC source: 0001225208-19-009716 · doc4.xml · derivative · entry 1 SMITH JAMES C · CIK 0001611777 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,345.882 Underlying: Common Stock · 966.644 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units represent deferred director's compensation (including dividend equivalents thereon) that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. F2 · derivative.expiration_date: These units represent deferred director's compensation (including dividend equivalents thereon) that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. Read SEC document |
| June 27, 2019 Filed Jul 1, 2019 22:48 UTC |
Gottlieb ScottDirector
|
GrantPhantom Stock Units · Derivative | 3,665.27 | $43.43 | $159,182.68 |
DisclosureSEC source: 0001225208-19-009708 · doc4.xml · derivative · entry 1 Gottlieb Scott · CIK 0001411359 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,665.27 Underlying: Common Stock · 3,665.27 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units represent deferred director's compensation that are settled in cash or common stock at the director's election, following the reporting person's retirement from the Board of Directors. F2 · derivative.expiration_date: These units represent deferred director's compensation that are settled in cash or common stock at the director's election, following the reporting person's retirement from the Board of Directors. Read SEC document |
| June 20, 2019 Filed Jun 21, 2019 20:08 UTC |
MACKENZIE ALEXANDER RExecutive Vice President
|
SaleCommon Stock | 30,000 | $44.00 | $1,320,000.00 |
DisclosureSEC source: 0001225208-19-009502 · doc4.xml · nonDerivative · entry 1 MACKENZIE ALEXANDER R · CIK 0001678459 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,094 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 1, 2019. Read SEC document |
| June 14, 2019 Filed Jun 17, 2019 22:18 UTC |
BOURLA ALBERTDirector · Chief Executive Officer
|
GrantPhantom Stock Units SSP · Derivative | 23 | $42.76 | $983.48 |
DisclosureSEC source: 0001225208-19-009332 · doc4.xml · derivative · entry 1 BOURLA ALBERT · CIK 0001595703 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,078 Underlying: Common Stock · 23 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| June 14, 2019 Filed Jun 17, 2019 22:19 UTC |
JOHNSON RADY AExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 4 | $42.76 | $171.04 |
DisclosureSEC source: 0001225208-19-009333 · doc4.xml · derivative · entry 1 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,897 Underlying: Common Stock · 4 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · shares: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| June 14, 2019 Filed Jun 17, 2019 22:19 UTC |
ROGERS DAWNExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 44 | $42.76 | $1,881.44 |
DisclosureSEC source: 0001225208-19-009334 · doc4.xml · derivative · entry 1 ROGERS DAWN · CIK 0001742308 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,691 Underlying: Common Stock · 44 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · shares: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| June 14, 2019 Filed Jun 17, 2019 22:19 UTC |
YOUNG JOHN DGroup President
|
GrantPhantom Stock Units SSP · Derivative | 10 | $42.76 | $427.60 |
DisclosureSEC source: 0001225208-19-009335 · doc4.xml · derivative · entry 1 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,727 Underlying: Common Stock · 10 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · shares: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| May 31, 2019 Filed Jun 4, 2019 01:34 UTC |
BOURLA ALBERTDirector · Chief Executive Officer
|
GrantPhantom Stock Units SSP · Derivative | 24 | $41.52 | $996.48 |
DisclosureSEC source: 0001225208-19-008748 · doc4.xml · derivative · entry 1 BOURLA ALBERT · CIK 0001595703 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,060 Underlying: Common Stock · 24 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| May 31, 2019 Filed Jun 4, 2019 01:34 UTC |
JOHNSON RADY AExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 4 | $41.52 | $166.08 |
DisclosureSEC source: 0001225208-19-008749 · doc4.xml · derivative · entry 1 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,896 Underlying: Common Stock · 4 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| May 31, 2019 Filed Jun 4, 2019 01:34 UTC |
ROGERS DAWNExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 45 | $41.52 | $1,868.40 |
DisclosureSEC source: 0001225208-19-008750 · doc4.xml · derivative · entry 1 ROGERS DAWN · CIK 0001742308 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,652 Underlying: Common Stock · 45 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| May 31, 2019 Filed Jun 4, 2019 01:35 UTC |
YOUNG JOHN DGroup President
|
GrantPhantom Stock Units SSP · Derivative | 10 | $41.52 | $415.20 |
DisclosureSEC source: 0001225208-19-008751 · doc4.xml · derivative · entry 1 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,722 Underlying: Common Stock · 10 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| May 29, 2019 Filed Sep 3, 2019 22:02 UTC |
Hwang AngelaGroup President
|
GiftCommon Stock | 240 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-012057 · doc4.xml · nonDerivative · entry 2 Hwang Angela · CIK 0001725474 · Group President 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 8,748 F2 · ownership.nature: The reporting person disclaims beneficial ownership of the shares held by spouse. Read SEC document |
| May 15, 2019 Filed May 17, 2019 19:49 UTC |
BOURLA ALBERTDirector · Chief Executive Officer
|
GrantPhantom Stock Units SSP · Derivative | 24 | $41.15 | $987.60 |
DisclosureSEC source: 0001225208-19-008146 · doc4.xml · derivative · entry 1 BOURLA ALBERT · CIK 0001595703 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,038 Underlying: Common Stock · 24 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| May 15, 2019 Filed May 17, 2019 19:49 UTC |
JOHNSON RADY AExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 4 | $41.15 | $164.60 |
DisclosureSEC source: 0001225208-19-008147 · doc4.xml · derivative · entry 1 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,893 Underlying: Common Stock · 4 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| May 15, 2019 Filed May 17, 2019 19:49 UTC |
ROGERS DAWNExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 46 | $41.15 | $1,892.90 |
DisclosureSEC source: 0001225208-19-008148 · doc4.xml · derivative · entry 1 ROGERS DAWN · CIK 0001742308 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,608 Underlying: Common Stock · 46 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| May 15, 2019 Filed May 17, 2019 19:49 UTC |
YOUNG JOHN DGroup President
|
GrantPhantom Stock Units SSP · Derivative | 10 | $41.15 | $411.50 |
DisclosureSEC source: 0001225208-19-008149 · doc4.xml · derivative · entry 1 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,714 Underlying: Common Stock · 10 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| April 30, 2019 Filed May 1, 2019 19:47 UTC |
ROGERS DAWNExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 46 | $40.61 | $1,868.06 |
DisclosureSEC source: 0001225208-19-007453 · doc4.xml · derivative · entry 3 ROGERS DAWN · CIK 0001742308 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,481 Underlying: Common Stock · 46 shares Expires not disclosed F2 · derivative.exercise_price: Each unit represents one phantom share of common stock. F3 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F3 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| April 30, 2019 Filed May 1, 2019 19:47 UTC |
BOURLA ALBERTDirector · Chief Executive Officer
|
GrantPhantom Stock Units SSP · Derivative | 25 | $40.61 | $1,015.25 |
DisclosureSEC source: 0001225208-19-007454 · doc4.xml · derivative · entry 1 BOURLA ALBERT · CIK 0001595703 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,894 Underlying: Common Stock · 25 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| April 30, 2019 Filed May 1, 2019 19:47 UTC |
JOHNSON RADY AExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 4 | $40.61 | $162.44 |
DisclosureSEC source: 0001225208-19-007455 · doc4.xml · derivative · entry 1 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,847 Underlying: Common Stock · 4 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| April 30, 2019 Filed May 1, 2019 19:47 UTC |
YOUNG JOHN DGroup President
|
GrantPhantom Stock Units SSP · Derivative | 10 | $40.61 | $406.10 |
DisclosureSEC source: 0001225208-19-007456 · doc4.xml · derivative · entry 1 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,603 Underlying: Common Stock · 10 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| April 29, 2019 Filed May 1, 2019 19:47 UTC |
ROGERS DAWNExecutive Vice President
|
Tax withholdingCommon Stock | 4,255 | $39.59 | $168,455.45 |
DisclosureSEC source: 0001225208-19-007453 · doc4.xml · nonDerivative · entry 1 ROGERS DAWN · CIK 0001742308 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,665 F1 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the vesting of restricted stock units (including dividend equivalents thereon). Read SEC document |
| April 25, 2019 Filed Apr 26, 2019 21:31 UTC |
BLAYLOCK RONALD EDirector
|
GrantPhantom Stock Units · Derivative | 4,859.884 | $39.61 | $192,500.01 |
DisclosureSEC source: 0001225208-19-007231 · doc4.xml · derivative · entry 1 BLAYLOCK RONALD E · CIK 0001214686 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,109.229 Underlying: Common Stock · 4,859.884 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · shares: Granted pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors. F3 · derivative.exercise_date: These units represent deferred director's compensation that are settled in cash or common stock at the director's election, following the reporting person's retirement from the Board of Directors. F3 · derivative.expiration_date: These units represent deferred director's compensation that are settled in cash or common stock at the director's election, following the reporting person's retirement from the Board of Directors. Read SEC document |
| April 25, 2019 Filed Apr 26, 2019 21:31 UTC |
CORNWELL W DONDirector
|
GrantPhantom Stock Units · Derivative | 4,859.884 | $39.61 | $192,500.01 |
DisclosureSEC source: 0001225208-19-007232 · doc4.xml · derivative · entry 1 CORNWELL W DON · CIK 0001174477 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,397.768 Underlying: Common Stock · 4,859.884 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · shares: Granted pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors. F3 · derivative.exercise_date: These units represent deferred director's compensation that are settled in cash or common stock at the director's election, following the reporting person's retirement from the Board of Directors. F3 · derivative.expiration_date: These units represent deferred director's compensation that are settled in cash or common stock at the director's election, following the reporting person's retirement from the Board of Directors. Read SEC document |
| April 25, 2019 Filed Apr 26, 2019 21:31 UTC |
Echevarria JosephDirector
|
GrantPhantom Stock Units · Derivative | 4,859.884 | $39.61 | $192,500.01 |
DisclosureSEC source: 0001225208-19-007233 · doc4.xml · derivative · entry 1 Echevarria Joseph · CIK 0001633137 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,410.044 Underlying: Common Stock · 4,859.884 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · shares: Granted pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors. F3 · derivative.exercise_date: These units represent deferred director's compensation that are settled in cash or common stock at the director's election, following the reporting person's retirement from the Board of Directors. F3 · derivative.expiration_date: These units represent deferred director's compensation that are settled in cash or common stock at the director's election, following the reporting person's retirement from the Board of Directors. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.